This is a divisional of copending application Ser. No. 492,519, filed on Mar. 12, 1990, now U.S. Pat. No. 5,154,914 .
FIELD OF THE INVENTION
The loss of detail in NMR spectra or lack of sufficient contrast in NMR images can limit the use of NMR analysis. Contrast agents have been employed in order to improve NMR imaging for non-invasive clinical diagnoses of mammalian hosts. The present invention relates to a class of compositions and a method for NMR imaging using NMR signal affecting amounts of a paramagnetic, diamagnetic or ferromagnetic metal ion chelated with a new lipophilic contrast agent, which are preferably new iminopolycarboxylate derivatives of fatty acids. Moreover, these compositions are also use ful for X-ray image analysis and in ultrasonic contrast analysis.
BACKGROUND OF THE INVENTION
Diagnostic imaging has emerged in recent years as a superior technique for noninvasive clinical diagnosis of heart, brain, kidney and other organs and tissues in mammalian hosts. Nuclear magnetic resonance (NMR) analysis, or magnetic resonance imaging (MRI), in many instances, requires contrast enhancement to ob tain useful images which delineate various aspects of the tissue, especially normal as contrasted with abnormal tissue.
The techniques of MRI or NMR imaging encompass the detection of certain atomic nuclei utilizing magnetic fields and radio-frequency radiation. It is similar in some respects to X-ray computed tomography (CT) in pro viding a cross-sectional display of the body organ anat omy with excellent resolution of soft tissue detail. In current use, the images produced constitute a map of the distribution density of protons and/or their relax ation times in organs and tissues. The MRI technique is advantageously non-invasive as it avoids the use of ionizing radiation.
The prior art discloses various techniques that can be employed for affecting an NMR signal in a host, of which a common technique is to introduce into the host a paramagnetic substance prior to NMR analysis which advantageously affects contrast, or selectively shifts the NMR signal. A large variety of compounds have found use in NMR and X-ray image analysis or as shift rea gents.
New compounds with low toxicity in vivo, high relaxivity, tissue and pathology specificity, and suffi cient tissue retention time but complete eventual clear ance are being sought. The well known ethylenedi aninetetraacetic acid (EDTA) and diethylenetriamine pentaacetic acid (DTPA) complexes with gadolinium (Gd) show low toxicity in vivo and rapid clearance rates but do not exhibit strong tissue specificity and long enough retention time, especially for myocardial tissue. Also their relaxivity decreases at hig magnetic fields already being introduced into the industry. Accord ingly, contrast enhancing agents with higher relaxivity, positive field profile, greater tissue specificity and suffi cient tissue retention time in addition to low toxicity are needed. One approach has been to modify EDTA and DTPA to achieve these goals.
U.S. Pat. No. 4, 647, 447 reports chelating agents for NMR analysis which include EDTA derivatives and DTPA derivatives differing significantly from the pres ent invention because they lack the lipophilic fatty acid moiety of the subject invention, and because of their inherently negative field profiles.
Several additional EDTA and DTPA derivatives are disclosed in U.S. Pat. Nos. 4, 687, 658; 4, 687, 659; 4, 746, 507; 4, 804, 529 and 4, 822, 594 . Collectively, these patents report ester, amide and polysaccharide deriva tives suitable for general MRI analysis but which, nev ertheless do not have the fatty acid derivatives and positive field profiles of the present invention.
Fatty acids and fatty acid analogs have been reported to accumulate in myocardial tissue when administered as radiopharmaceuticals. U.S. Pat. No. 4, 763, 358 dis closes that branched chain fatty acids have utility in cardiac imaging using radioactive iodine as the contrast moiety.
In a study of the biological distribution of chemical analogs of fatty acids and long chain hydrocarbons containing a strong chelating agent, Karesh, S. M. et al. (1977) J. Pharm. Sci 66: 225-228, describe radiopharma ceutical cobalt (Co) and technicium (Tc) complexes wherein the alkyl end of a fatty acid molecule is cova lently bound to a carboxyl group on the chelating agent, forming an ester derivative of the chelating agent. In contrast, the subject chelating agents are ester deriva tives of the fatty acid and will therefore be more lipo philic due to the long, free alkyl chain then the Karesh compounds which exhibit significant hydrophilic char acter due to the free carboxylic acid ends. Moreover, Karesh reports that the compounds under investigation studied were not sufficient biological analogs to act as tracers for fatty acid metabolism in the myocardium. Accordingly, the present invention provides contrast enhancing agents for diagnostic image analysis which are lipophilic in nature because of a free hydrocarbon chain coupled via an ester linkage with a strong chelat ing agent, such as polyaminopolycarboxylic acid deriv atives, especially EDTA and DTPA derivatives.
SUMMARY OF THE INVENTION
This invention relates to lipophilic contrast enhanc ing agents for diagnostic image analysis, preferably for NMR or MRI analysis, but which also find utility in X-ray image analysis and ultrasonic analysis. While generally described as contrast enhancing agents, it is understood that these agents can also act as NMR shift reagents. Specifically, therefore, the contrast enhancing agents are complexing acids, or a salt thereof, and at least one paramagnetic, diamagnetic or ferromagnetic metalion, with the complexing acids having at least one fatty acid chain as represented by the formula The preferred compounds are polyaminopolycar boxylic acids derivatives, especially EDTA derivatives having one or two fatty acid moieties as provided above, and having a carboxymethylacetamide replacing at least one acetic acid group, and even more preferably replacing two acetic acid groups. Other preferred com pounds are DTPA derivatives having at least one fatty acid moiety as provided above.
Conjugates of the contrast enhancing agents of the present invention are also provided. Liposomes, prote ins, peptides, antibodies, and other physiological agents can be conjugated with contrast enhancing agents for diagnostic image analysis. Another aspect of the invention is directed to a method for diagnostic analysis by administering the 10 15 20 25 30 subject contrast enhancing agents or conjugates thereof 35 to a host, preferably a mammalian host, in an amount sufficient to effect the desired contrast and then subject ing the host to diagnostic analysis. Preferably diagnostic analysis is NMR analysis; including and especially pre ferred, NMR imaging analysis (or MRI). Further, the subject compounds are useful in diagnostic analysis by X-ray image analysis or ultrasonic analysis.
A further aspect contemplated by the instant inven tion is a method of tissue specific imaging with a tissue specific contrast enhancing agent as provided herein.
Yet another aspect of the invention provides pharma ceutical compositions containing the subject contrast enhancing agents or conjugates thereof and a pharma ceutically acceptable carrier.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to complexing acids and salts thereof which when combined with a para magnetic, ferromagnetic or diamagnetic metal ion form contrast enhancing agents, wherein the acids are repre sented by the formula
wherein a is 0 to 5; 45 50 55 60 65 4. b is 1 to 5; each of a and b can be the same or different; each R is the same or different and is hydrogen, lower alkyl, hydroxy, halo, lower alkoxy, aryl, or lower aral kyl;
at least one of R1, R2, R3, R4 or X has the formula O Rs-C-Owherein R5 is a saturated or unsaturated hydrocarbon chain having 6 to 30 carbon atoms; and the others of R1, R2, R3, R4 or X are hydrogen, hydroxyl, -COOR6, -CONR7Rs or a chelating moiety wherein R5, R7, and Rs are the same or different and represent hydrogen, lower alkyl, lower alkoxy, lower carboxyalkylene, or a chelating moiety.
By "complexing acid' herein is meant an acid and may include a Lewis acid, which acts as a ligand for the metals of interest thereby forming a chelate.
As used herein, the term lower alkyl, when used singly or in combination, refer to alkyl groups contain ing one to six carbon atoms. They may be straight chain or branched and include such groups as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl and the like. The preferred alkyl groups contain one to four carbon atonS.
The term aryl, when used alone or in combination, refer to an aromatic ring containing six to ten ring car bon atoms. The aryl group includes phenyl, and 1-or 2-naphthyl. The preferred aryl group is phenyl.
The term aralkyl refers to aryl groups as described above which have alkyl groups as ring substituents. The most preferred aralkyl group is benzyl.
As used herein, lower alkoxy refers to a lower alkyl group having at least one hydroxyl substituent. Halo refers to the halogen compounds, especially bromine, iodine, chlorine and fluorine.
The term lower carboxyalkylene refers to groups having the formula where n may vary from 1 to 5. Representative groups include carboxymethylene, carboxyethylene, carboxy propylene, carboxybutylene, and carboxypentylene. The alkalene groups may, optionally, be branched. Es pecially preferred are carboxymethylene, carboxyethy lene, and carboxypropylene.
A chelating moiety is herein defined to be any acidic group, including groups from Lewis acids, capable of forming a complex with the metal ions of the present invention. Such moieties include carboxylic acids, phos phoric acids, amines and the like.
The term saturated hydrocarbon chain refers to an alkyl chain which contains no double or triple bonds. Examples of chains contemplated for use herein include myristyl, palmityl, lauryl, stearyl, caproyl, capryl, cap rylyl, arachidyl, melissyl and the like. An unsaturated hydrocarbon chain contains at least one double bond or triple bond and may contain several such bonds. Exam ples of unsaturated hydrocarbon chains as contemplated herein include oleyl, myristoleyl, palmitoleyl, elaidyl, linoleyl, arachidonyl, y-linolenyl and the like. 5,242,681 5 Preferred compounds of the invention are those wherein one or two of the substituents R1-R4 and X are O Rs-C-O-, with R5 being a saturated or unsaturated hydrocarbon chain having 6 to 30 carbon atoms, and more preferably 8 to 24 carbon atoms. These preferred compounds should also have a sufficient number of complexing acid groups available for chelating at least one metalion. For example, such chelating groups may be two or more carboxylates or chelating moieties as defined herein. The complexing acid groups thus are provided by the non-lipophilic R1-R4 and X groups, or when one of these groups is defined as -CONR7Rs, then R7 and R8 may provide the complexing acid groups.
Preferred compounds are those wherein a is 0 or 1, and b is 1 to 5, more preferably i to 3. When a is 0, preferred compounds are those where R is hydrogen; R1 is The compounds of the invention can be prepared by art recognized methods. For example, compounds hav ing acetamide substituents can be prepared by alkylat ling X with a haloacetamide (with the acetamide group being substituted with an aralkyl carboxyalkylene if desirable) followed by monoaralkyloxycarbonylation on one of the hydroxyl groups and acylation of the other to obtain a monoacylated agent. Diacylation can be done directly after alkylation. In either case, the aralkyl groups of the carboxylates are removed by catalytic hydrogenation to obtain the complexing acid.
One specific synthetic route available to produce two of the preferred compounds is described and illustrated in Scheme 1 below (compound numbers are as defined in the Examples).
Null
Intermediate 2 can be prepared by alkylation of N,N'bis(2-hydroxyethyl)-ethylenedianine with compound 1. Direct monomyristoylation of compound 2 using stoi chiometric amounts of myristoyl chloride can result in low yield and difficult chromatographic purification. Thus, following monobenzyloxycarbonylation on one of the hydroxyl groups in compound 2, the resulting monoacylated intermediate is subsequent treated with myristoyl chloride under dimethyl aminopyridine (DMAP) to give compound 3. Similarly, bismyristoyla tion of compound 2 affords compound 4 with 66% yield. Subsequently, debenzylation of 3 and 4 by cata lytic hydrogenation lead to target compounds 5 and 6.
Other compounds of the invention represented by the
R2 R4 5,242,681 7 wherein R1-R8, X, a and b are as defined above, are also prepared by art recognized methods. For example, amino alcohols can be prepared by alkylation of with an alkyl halide, and then further alkylated with aralkyl halocarboxyalkylenes to obtain an intermediate
wherein X and R2-R4 are COOR9 and R9 is aralkyl (e.g. benzyl). The above compound can be acylated, prefera bly with an alkyl halide, followed by catalytic hydroge nation to remove the aralkyl groups and yield the de sired compound. R groups can be introduced subse quent to the synthesis or by employing appropriately substituted alkylhalides or aralkyl halocarboxyalkylenes at the appropriate step. Moreover, similar production methods can be employed when the starting material is a compound of the formula Alternately, a starting aminoalcohol of the formula can be alkylated with iodoacetamide to form a tertiary amine which can be subjected to reduction of the keto group and further alkylation with an aralkyl halocar boxyalkylene. Acylation and catalytic hydrogenation are then conducted as before, to yield the desired com pounds.
To illustrate a synthetic route to two preferred com pounds of this invention are described below and illus trated in Scheme II (the compound numbers refer to those used in the Examples). Specifically, ligand 11 can be obtained by alkylation of diethylenetriamine with chloropropanol and benzyl bromo acetate, followed by acylation with myristoyl chloride and catalytic hydrogenation. For the prepara tion of ligand 16, alkylation of amino alcohol 12 with iodoacetamide is followed by borane reduction and treatment with benzyl bromoacetate to afford interme diate 14. Subsequently, acylation of compound 14 with myristoyl chloride and catalytic hydrogenation give compound 16.
The current enhancing agent comprises a metal ion selected from a member of the group consisting of para magnetic metal ions, diamagnetic metal ions, ferromag netic metal ions, or X-ray absorptive metal ions.
For NMR or MRI, the preferred metal ions en ployed in the agent of the present invention are para magnetic metal ions since metal ions of this type gener ally have an enhanced relaxation effect on the surround ing water molecules in a mammalian host where the agent is taken up and generally, produce the enhanced contrast results in mammalian hosts, Paramagnetic metal ions by definition are those metal ions that carry unpaired electrons.
Ferromagnetic metal ions may also be employed in this respect and include those metal ions whose internal magnetic moments spontaneously organize in a com mon direction.
Diamagnetic metal ions may also be employed which are those metal ions that do not carry unpaired elec trons. These metal ions position themselves at right angles to magnetic lines of force, and include for exam ple, the alkaline earth metal ions (Group IIA of the Periodic ions with suitable ions, for example, including chromi um(III), manganese(II), iron(III), iron(II), cobalt(II), nickel(II), copper(II), praseodymium(III), neodymium (III), samarium(III) and ytterbium(III). Because of their very strong magnetic moments, gadolinium(III), terbi um(III), dysprosium(III), holmium(III), and erbium(III) arc preferred.
If the agents according to the invention are for use in X-ray diagnosis, the metalion shall be derived from an element with a higher atomic number to achieve a suffi cient absorption of X-rays. It has been found that con trast agents with metal ions of elements with atomic numbers of 57 to 83 inclusive are suitable for this pur pose. These include, for example, lanthanum(III), the above mentioned ions of the lanthanide group, gold (III), lead(II) or, especially, bismuth(III).
All of the agents according to the invention, also intended for use both in NMR and X-ray diagnosis, are also suitable for use in ultrasonic diagnosis.
Production of the contrast agents are also known or can be performed fully conventionally as known in the art, e.g., in processes in which the metal oxide or a metal salt (for example, nitrate, chloride or sulfate) of an ele ment with an atomic number of 21 to 29, 42 to 44 or 57 to 83 is dissolved or suspended in water and/or a lower alcohol (such as methyl, ethyl or isopropyl alcohol) and added to a solution or suspension of the equivalent amount of the complexing acid in water, a lower alco hol, or other suitable organic solvent (such as pyridine) and stirred, if necessary, with heating moderately or to the boiling point, until the reaction is completed. If the contrast agent that is formed is insoluble in the solvent that is used, it is isolated by filtering. If it is soluble, it can be isolated by evaporation of the solvent to dryness, for example, by spray drying.
If acid groups are still present in the resulting contrast agent, it is often advantageous to convert the acidic salt into a neutral salt by reaction with inorganic and/or organic bases or amino acids. which form physiologi cally biocompatible cations, and isolate them. In many cases, the procedure is even unavoidable since the disso ciation of the complex salt is moved toward neutrality to such an extent by a shift in the pH value during the preparation that only in this way is the isolation of ho mogeneous products or at least their purification made possible. Neutralization is advantageously performed with organic bases or basic amino acids. It can also be advantageous, however, to perform the neutralization by means of inorganic bases (hydroxides, carbonates or bicarbonates) of sodium, potassium or lithium.
To produce the neutral salts, enough of the desired base can be added to the acidic contrast agents in an aqueous solution or suspension that the point of neutral ity is reached. The resulting solution can then be con centrated to dryness in vacuo. It is often advantageous to precipitate the neutral salts by addition of solvents miscible with water, for examples, lower alcohols (methyl, ethyl, isopropyl alcohols, etc.), lower ketones (acetone, etc.), polar ethers (tetrahydrofuran, dioxane, 1,2-dimethoxyethane, etc.) and thus obtain crystallizates that isolate easily and purify well. It has been found particularly advantageous to add the desired bases to the reaction mixture even during complexing and thus eliminate a process stage.
If the acidic contrast agent contain several free acid groups, it is then often advantageous to produce neutral mixed salts which contain both inorganic and organic physiologically biocompatible cations as counterions. This can be done, for example, by reacting the complex ing acids in an aqueous suspension or solution with the oxide or salt of the element supplying the metalion and less than the full amount of an organic base necessary for neutralization, e.g., half, isolating the complex that is formed, purifying it, if desired, and then adding it to the amount of inorganic base necessary for complete neu tralization. The sequence of adding the bases can also be reversed.
The contrast enhancing agents can be coupled as conjugates with biomolecules that are known to con centrate in an organ or part of an organ to be examined. Conjugates are also useful when the subject contrast agents are provided as shift reagents. These bi omolecules include, for example, hormones such as insulin, prostaglandins, steroid hormones, amino sugars, peptides, proteins, lipids, etc. Conjugates with albu mins, such as human serum albumin, or antibodies, for example, monoclonal antibodies specific to tumor associated antigens, antimyosin, or exhibiting a desired diagnostic specificity provide a further battery of tools for diagnostic image analysis. For example, the diagnos tic media formed therefrom are suitable for use in tumor and infarct diagnosis. Conjugates with liposomes, or by inclusion of the salts in liposomes, in both cases which, for example, are used as unilamellar or multilamellar phosphatidylcholine-cholesterol vesicles, are also suit able for diagnostic probes. The liposomes may be fur ther modified to impart target specificity, i.e. attach ment of antibodies, hormones, peptides, proteins and the like. Conjugating can be conventionally effected either via a carboxyl group of the complexing acid, and in the case of proteins especially to amino or thiol linkages. Moreover, several acid radicals can be partially bonded to the macromolecular biomolecule in the conjugation of the complex salts with proteins, peptides or lipids. In this case, each complexing acid radical can carry a metal ion. If the complexing acids are not bonded to biomolecules, they optionally carry two metal ions usually and especially one metal ion.
Liposomes are formed by conventional means and these techniques are well known and widely available to the ordinary-skilled artisan. One example of liposome formation is described by Grant G. W. M. et al. (1989) Magn. Reson. Med. 11:236 . Any lipid such as the phos pholipids of phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, cardi olipins, lysophospholipids, or other lipids such as glyco lipids, sphingolipids, fatty acids, and glycerides (mono, di or tri) are suitable for incorporation into liposomes. Moreover, the liposomes may contain other compo nents such as cholesterol or protein. When protein is present, the liposomes are proteoliposomes. Further, the chain lengths of the lipids can be varied as desired, for example as herein described in the definition of Rs.
For the subject invention liposomes having the con trast enhancing agents incorporated therein may be prepared by the methods of Kalbalka, G. W. et al. Another aspect of the present invention is directed to a method for diagnostic analysis by administering the subject contrast enhancing agents or conjugates thereof to a host, preferably a mammalian host, in an amount sufficient to effect the desired contrast (or shift) and then subjecting the host to diagnostic analysis. Prefera bly diagnostic analysis is NMR analysis; including and especially preferred, NMR imaging analysis (or MRI). 5,242,681 11 Further, the subject compounds are useful in diagnostic analysis by X-ray image analysis or ultrasonic analysis. While described primarily as contrast enhancing agents, the subject agents can act as NMR shift reagents and such use is contemplated by the methods herein.
The subject contrast enhancing agents are adminis tered in an amount sufficient to effect the desired con trast. For NMR, this amount is an NMR signal affecting amount of said agent, i.e., any amount of said agent that will alter the spin-lattice, spin-spin or spin-echo relax ation times of an NMR signal or for a shift reagent, selectively shift the spectral position of a resonant nu cleus relative to other similar nuclei. This alteration is effected in a manner in order to enhance the signals received from the specimen under analysis either by reducing the aforementioned relaxation times or by increasing them with respect to an area of the host or the host perse which has had the complex administered to it. Shift reagents thus also distinction of signals in a specimen. In another embodiment, the NMR signal affecting amount of said agent is that amount which in addition to changing the relaxation times of the NMR signals in the host, will also change such relaxation times sufficiently so that sharper lines of definition or higher contrast is obtained between those parts of the Another parameter which can be measured is the density p (rho) of the protons in the medium. As a first approximation, it represents the quantity of free water contained in the sample.
The image by nuclear magnetic resonance represents the distribution of these parameters p, T1, T2 or their combination. The contrast between a given tissue and the adjacent tissues increases as a function of the tissues containing more or less water or mobile protons and differing relaxation times. It is also possible to modify the contrast by varying one or more of these parame ters. Experience has shown that it was of greater inter est to modify the relaxation time to improve the con trast of the image which can be accomplished, for exam ple, with contrast enhancing agents provided herein. The density of the protons (in practice those of water and lipids) varies little between individual organs and often less between normal and pathological tissues. However, the relaxation characteristics are dependent on a larger number of factors (microscopic dynamics of the molecules, chemical exchange, paramagnetic dis turbances, etc.), which are much more variable. The at least relative technical possibilities of selecting different parameters for obtaining the final image (experimen tally echoes of spins aiding the function of T2, or experi mentally reversal-recovery of the magnetization per mitting the local measurement of Ti) have shown the significance of the method.
A detailed discussion of NMR and theoretical consid erations in selecting the appropriate parameters for diagnostic analysis is rendered in U.S. Pat. No. 4,749,560 which is incorporated herein by reference, e.g. CAT scans, X-ray image analysis and ultrasonic diagnosis are conducted in accordance with well-estab lished techniques. Moreover, the present method of diagnostic analysis allows tissue-or organ-specific diagnostic analysis to be achieved. For example, the subject contrast enhancing agents can exhibit organ and tissue specificity, e.g., bidifferential distribution, especially in myocardial tis sue since these agents exhibit a lipophilic nature. Fur ther specificity can be gained when the subject contrast enhancing agents are conjugated to molecules which themselves exhibit target specificity as described herein before. All such variations of the present methods are contemplated by the invention.
The present contrast agents may be administered to a host as a pharmaceutical composition in a contrast enhancing amount. The pharmaceutical compositions contain a contrast-enhancing dosage of the contrast agents according to the invention together with a phar maceutically acceptable carrier. The compositions can be administered by well-known routes including oral, intravenous (if soluble) intramuscular, intranasal, intra dermal, subcutaneous, parenteral, enteral and the like. Depending on the route of administration, the pharma ceutical composition may require protective coatings.
The pharmaceutical forms suitable for injectionable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the ultimate solution form must be sterile and fluid. Typical carriers include a solvent or dispersion medium contain ing, for example, water, buffered aqueous solutions (i.e., biocompatible buffers), ethanol, polyol (glycerol, prop ylene glycol, polyethylene glycol and the like), suitable mixtures thereof, surfactants or vegetable oils. Steriliza tion can be accomplished by any art recognized tech nique, including but not limited to, addition of antibac terial or antifungal agents, for example, paraben, chlo robutanol, phenol, sorbic acid, thimerosal, and the like. Further, isotonic agents, such as sugars or sodium chlo ride may be incorporated in the subject compositions.
Production of sterile injectable solutions containing the subject contrast agent is accomplished by incorpo rating these agents in the required amount in the appro priate solvent with various ingredients enumerated above, as required, followed by sterilization, preferably filter sterilization. To obtain a sterile powder, the above solutions are vacuum-dried or freeze-dried as necessary.
When the contrast agents are administered orally, the pharmaceutical compositions thereof containing an ef fective dosage of the contrast agent, may also contain an inert diluent, an assimilable edible carrier and the like, be in hard or soft shell gelatin capsules, be con pressed into tablets, or may be in an elixir, suspension, syrup or the like.
The subject contrast agents are thus compounded for convenient and effective administration in pharmaceuti cally effective amounts with a suitable pharmaceuti cally acceptable carrier in a dosage which affects con trast enhancement. These amounts are preferably about 1 umole to 1 mole of the contrast agent per liter and are administered in doses of about 0.001 to 5 mmole/kg body weight. Preferred compositions provide effective dosages of contrast agents in the range of about 0.001-5 mmole/kg for NMR diagnostics, preferably about 0.005-0.5 mmole/kg; in the range of about 0.1-5 mmo le/kg for X-ray diagnostics; and in the range of about 0.1-5 mmole/kg for ultrasound diagnostics.
As used herein, a pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coat ings, antibacterial and antifungal agents, isotonic agents, 5,242,681 13 and the like. The use of such media and agents are well known in the art.
The following Examples further illustrate the inven tion.
EXAMPLE 1 Materials and Methods
Melting points were determined in open capillaries with a Gallenkamp melting point apparatus and are uncorrected. High resolution proton NMR spectra to confirm intermediates and identify products, were re corded on a Bruker AM-360 instrument. Either Me4Si (CDCl3, DMSO-d6) or 3-(trimethylsilyl)-propionic 2,2,3,3-d acid, sodium salt (TSP) (D2O) were used as internal standard. Chemical shifts (in ppm) are reported along with peak multiplicities: br, broad; m, multiplet; t, triplet; d, doublet; s, singlet. Elemental analyses were performed by Atlantic Microlab Inc. Norcross, Ga. EXAMPLE 2 A. N,N-Bis(benzyloxycarbonylmethyl)-bromoaceta mide (1): A solution of dibenzyl iminodiacetate (9.7 g, 0.031 mol) and triethylamine (4.05 g, 0.04 mol) in 30 ml of carbon tetrachloride was added dropwise to a solu tion of bromoacetyl bromide (8.88g, 0.044 mol) in 20 ml of carbon tetrachloride at O C. and stirring was contin ued for 30 min. After addition of water, the organic layer was washed with saturated-NaHCO3 solution and saturated-brine, dried with MgSO4, filtered and concen trated under reduced pressure. in 5 ml of DMF was treated with a solution of bromo compound 1 (5.21 g, 0.012 mol) in 5 ml of DMF at 0°C. and stirring was continued for 2 hat room temperature.
The reaction mixture was diluted with EtOAc and the organic solution was washed with 0.5 N-HCl, 0.5NNaOH and saturated brine. The organic layer was concentrated under reduced pressure affording an al kylated intermediate 2 used for the next step without any further purification. To a solution of compound 2 and DMAP (0.86 g, 0.007 mol) in 10 ml of dry THF a solution of benzyl chloroformate (1.2g, 0.007 mol) in 5 ml of dry THF was added dropwise at 0°C. and stirring was continued for 1 h at the same temperature and for 2h at room temperature. Subsequently, the reaction mixture was treated with a solution of DMAP (0.86 g, 0.007 mol) in 10 ml of dry THF, followed by dropwise addition of a solution of myristoyl chloride (1.61 g, 0.0065 mol) in 10 ml of dry THF. After stirring the reaction mixture at room temperature overnight, the reaction mixture was diluted with chloroform and the organic layer was washed with saturated brine. Purifi was prepared by the methodology analogous to that employed in the preparation of compound 5. Thus, compound 4 (2.28 g, 1.79 mmol) was catalytically hy drogenated under the conditions employed in Example 2C and yielded 1.15 g (70%) of compound 6. NMR (20% K2CO3 in D2O): 80.88 (t,6H), 1.29 (brs,40H), 1.5-1.7 (m,4H), 2.38 (t,4H), 2.7-3.1 (m,8H), 3.52 (brs,4H), 3.91 (brs,8H), 4.20 (t,4H).
EXAMPLE 4
A. Tetrabenzyl N-(3-hydroxypropyl)diethylenetria mine-N,N',N',N'-tetraacetate(9) : A solution of ami noalcohol 8 (4.03 g, 0.025 mol) (Timakova, L. M. et al. (1977) Zh. Obsh. Khim. 47: 691) and triethylamine (12.65 g, 0.125 mol) in 35 ml of DMF was added dropwise to a cold (O'C.) solution of benzyl bromoacetate (28.64g, 0.125 mol) in 25 ml of DMF during a period of 1 h, and the resulting mixture was stirred overnight at room temperature. After partition of the mixture between EtOAc and water, the organic layer was washed with saturated brine, dried with MgSO4, filtered and concen trated under reduced pressure. The residue was purified through silica gel column using EtOAc:hexane (3:1) as eluent, affording 8.6 g (46%) of compound 9. NMR (CDCl3): 81.5-1.7 (m,2H), 2.6-2.9 (m, 10H), 3.38 (s.2H), 3.47 (s.2H), 3.60 (s,4H), 3.70 (t,2H), 4.88 (brs, 1H), 5.09 (s, 2H), 5.10 (s,4H), 5.11 (s.2H), 7.33 (s.20H).
B. Tetrabenzyl N-(3-Myristoyloxypropyl)diethylene triamine-N,N',N',N'-tetraacetate(10) : To a solution of hydroxyester 9 (1.13 g, 1.5 mmol) and triethylamine (0.18 g, 1.8 mmol) in 7 ml of carbon tetrachloride, a solution of myristoyl chloride (0.45 g, 1.8 mmol) in 10 ml of carbon tetrachloride was added at O' C. and the resulting solution was stirred overnight at room temper ature. The CCI layer was washed with saturated brine and concentrated. The residue was purified by silica gel column chromatography hexane: EtOAc (2:1) afford 5,242,681 15 ing 0.83 g (57%) of compound 10. NMR (CDCl3): 60.88 (t,3H), 1.25 (brs,20H), 1.5-1.8 (m,4H), 2.25 (t,2H), 2.5-3.0 (n,8H), 3.39 (s.2H), 3.45 (s.2H), 3.61 (s4H), 4.04 (t,2H), 5.10 (s,8H), 7.33 (brs,20H). (14): To a suspension of amide 13 (2.518 g, 0.0133 mol) in 50 ml of dry THF, 130 ml of BH3 THF was added dropwise at 0° C., and the resulting mixture was stirred overnight.
Methanol (20 ml) was added to the reaction mixture at O C. After evaporation of the solvent, the residue was dissolved in methanol and saturated with HCl gas, fol lowed by reflux of the reaction solution for 2 h. The residue, obtained by the removal of methanol in 25 ml of DMF, was treated with Et3N (15 ml) and the solid was removed by filtration. The filtrate was added to a solu tion of benzyl bromacetate (15.23 g, 0.0665 mol) in 15 ml of DMF at 0° C. and stirring was continued over night. The reaction mixture was diluted with EtOAc and the organic solution was washed with saturated brine, dried with MgSO4, filtered and concentrated under reduced pressure. Purification through a silica gel column using CHCl3:methanol (15:1) as eluent afforded 4.98 g (50%) of compound 14. NMR (CDCl3): 81.5-1.6 (n,2H), 2.4-2.6 (m,6H), 2.85 (t,4H), 3.60 (s,8H), 3.67 (t2H), 5.11 (s,8H), 7.2-7.4 (m,20H).
C. N-(3-Myristoyloxypropyl)-N,N-bis(2-N',N'-bis(benzyloxycarbonylmethyl)nitriloethylamine (15) Preparation of Gd Complexes of Compounds 5 and 6 Gd complexes of target compounds 5 and 6 were prepared according to the procedure of Kabalka, et al. Thus a solution of GdCl36H2O(0.39 g, 1.05 mmol) in 2 ml of distilled water was added dropwise to a solution of compound 5 (0.494 g, 0.7 mmol) in 25 ml of pyridine and stirring was continued for 30 min at room tempera ture. The solvent was completely removed under re duced pressure and the residue was suspended in dis tilled water to remove excess GdCl3. The solid in water was collected by filtration and dried under vacuum affording 0.626 g (96%) of Gd complexed compound 5. Anal. calcd. for C32H53N4O13Gd 4H2O: C, 41.28; H, 6.60; N, 6.02. Found: C, 41.21; H, 6.46; N, 5.81. Similarly, compound 6 (0.641 g, 0.7 mmol) yielded 0.706 g (91%) of Gd complexed compound 6. Anal. calcd. for C46H9N4O14Cid 2H2O: C, 49.98; H, 7.57; N, 5.07. Found: C, 49.89; H, 7.65; N, 5.00. EXAMPLE 7 Gd complexes with compound 11 and 16 were pre pared as described in Example 6. EXAMPLE 8
Incorporation of Gd Complexes 5 and 6 in Liposomes
Liposomes were prepared by the procedure of Ka balka et al., as modified by Grant, et al., by mixing either 4.7 mg of Gd complex 5 or 5.6 mg of Gd complex 6, 2 mg of cholesterol and 20 mg of egg lecithin (20 mg/ml in chloroform molar ratio 1:1:5, Avanti Co.) in 8 ml of chloroform and methanol (2:1). N2 gas was intro duced into the mixture to remove the solvent and the residue was dried for 2 days under vacuum. The result ing dry lipids were suspended in 5 ml of 0.9% saline solution (pH 7.0) affording a 1 mM solution of the Gd complex. The suspension was sonicated for 2 h at 4 C. A Branson Model W-350 sonifier with a microtip probe was used with the power setting in pulsed mode (50% duty cycle) at 3. Subsequently, the liposomes were cen trifuged at 2000 rpm for 30 min at 4 C. to remove titanium particles generated by the sonicator probe tip. The supernatant solution of the liposomes was used for measurement of relaxivities. EXAMPLE 9
NMR Relaxivity Measurements
The 1:1 complexes of Gd3+ with compounds 5, 6, 11 and 16 as ligands were used for water proton NMR relaxation rate (1/T) measurements at pH 7.0 as a func tion of the concentration of each complex (0.2-1.0 mM) on IBM PC-10 (10 MHz, 0.23T) and IBM PC-20 (20 MHz 0.47T) Multispec NMR instruments. 1/T mea surements were taken at a probe temperature of 40° C. The average of two consecutive 1/T measurements is taken as the final relaxation rate value. From the slope of 1/T vs Gd complex), the relaxivity of each complex is determined. The resulting relaxivities are presented in Table 1 . The relaxivities of 5 and 6 are significantly larger than those of Gd(EDTA) and Gd(DTPA) and are similar to those of uncomplexed Gdt aquoion Lauffer, R. B. et al. (1985) Magn. Reson. Imaging 3: 11; Koenig, S. H. et al. (1984) Mag. Reson. Med. 1496. The relaxivities of 11 and 16, however, are similar to those of Gd(EDTA) and Gd(DTPA). Relaxativities of com pounds 5 and 6 increase from 0.23T to 0.47T, whereas those of compounds 11 and 16 decrease with increasing magnetic field. When complexes 5 and 6 are incorpo rated into liposomes, a 51-86% increase of relaxivity at both magnetic fields was observed. We claim:
1. A method for X-ray image analysis or ultrasonic analysis comprising administering to a host a contrast enhancing amount of a contrast enhancing agent which comprises a complexing acid or a salt thereof and at least one metalion of an element with an atomic number 21 to 29, 42 to 44 or 57 to 83, wherein said acid has the wherein a is 0 to 5; b is 1 to 5; each of a and b can be the same or different; each R is hydrogen, lower alkyl, hydroxy, halo, lower alkyoxy, aryl, or lower aralkyl; at least one of R1, R2, R3, R4 or X has the formula O Rs-C-Owherein R5 is a saturated or unsaturated hydrocar bon chain having 6 to 30 carbon atoms; and the others of R, R2, R3, R4, or X are hydrogen, hy droxyl, -COOR6, -CONR7R8 or a chelating moiety wherein R6, R7, and R3 are the same or different and represent hydrogen, lower alkyl, lower alkoxy, lower carboxyalkylene, or a chelating moiety; and subjecting said host to X-ray image analysis or ultrasonic analysis.
2. The method of claim 1 wherein said host is a mam mal.
3. The method of claim 1, wherein R5 is a hydrocar bon chain substituted with a lower alkyl, hydroxyl, lower alkoxy or halogen moiety. 7. The method of claim 6, wherein R is hydrogen, R2, R3, R4 and X are COOR6, and R6 is hydrogen.
8. The method of claim 1 wherein X is O RS-C-O-.
9. The method of claim 8 wherein R is hydrogen, R1, R2, R3 and R4 are COOR6, and R5 is hydrogen.
10. The method of claim 6 wherein R is hydrogen, R2 and R4 are -CONR7Rs, R3 is hydroxyl, and R7 and Rs are lower carboxyalkylene.
11. The method of claim 10, wherein a is 0. 
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